Trial Profile

Combination Treatment of Nivolumab, Ipilimumab, Intratumoral CMP-001 and Radiosurgery for Liver Metastases in Colorectal Carcinoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Vidutolimod (Primary) ; Vidutolimod (Primary)
Indications Carcinoma; Colorectal cancer; Liver metastases
Focus Adverse reactions

Most Recent Events

21 Jan 2023 Status changed to completed as per results presented at the 2023 Gastrointestinal Cancers Symposium.
21 Jan 2023 Results assessing the efficacy and safety of intratumoral vidutolimod for metastatic colorectal carcinoma, presented at the 2023 Gastrointestinal Cancers Symposium.
20 May 2022 Planned End Date changed from 31 May 2021 to 25 May 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com